A Systematic Review of Interleukin-31 Inhibitors in the Treatment of Prurigo Nodularis

A Systematic Review of Interleukin-31 Inhibitors in the Treatment of Prurigo Nodularis Publisher Pubmed

Nilforoushzadeh MA^{1, 2} ; Heidari N^{1, 2, 3} ; Ghane Y^{1, 2, 4} ; Heidari A^{1, 2, 5} ; Hajikarimhamedani A^{1, 5} ; Hosseini S^{1, 6} ; Jaffary F^{1, 2} ; Najar Nobari M⁷ ; Tavakolzadeh P^{1, 3} ; Najar Nobari N^{1, 2, 8}

Show Affiliations

1. Skin Repair Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2. Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran
3. School of Medicine, Iran University of Medical Sciences, Tehran, Iran
4. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
5. Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
6. School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
7. Department of Orofacial Pain and Dysfunction, UCLA School of Dentistry, Los Angeles, CA, United States
8. Department of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Source: Inflammopharmacology Published:2024

Abstract

Background: Prurigo nodularis (PN) is a neuroimmunological skin disease. Severe itching is the most challenging symptom which affects patients’ quality of life. T helper 2-derived cytokines, such as interleukin-31 and oncostatin M (OSM), play a crucial role in PN pathogenesis. Nemolizumab and vixarelimab are two biologics acting as IL-31 inhibitors. Vixarelimab also suppresses the OSM activity. This systematic review evaluates the efficacy and safety of nemolizumab and vixarelimab in PN management. Methods: A systematic search was conducted in PubMed/Medline, Ovid Embase, and Web of Science up to September 17th, 2023. Clinical trials and cohort studies published in English were included. Results: Among a total of 96 relevant records, five were included. The results of four studies with 452 patients using nemolizumab showed that a significantly higher percentage of patients treated with nemolizumab demonstrated a reduction in peak pruritus numerical rating scale (PP-NRS) and investigator’s global assessment along with improved sleep disturbance (SD) and quality of life than the placebo group. Moreover, one study administered vixarelimab to 49 PN patients, and their finding illustrated a higher rate of subjects who received vixarelimab experienced ≥ 4-point diminution in worst itch NRS, visual analog scale, healing of representative lesions, and SD quality compared to the placebo group. Conclusions: IL-31 inhibitors suggest distinct advantages in improving pruritus, sleep quality, and overall quality of life in subjects with moderate-to-severe PN. Further clinical studies are recommended to compare the effectiveness of these biologics to other therapeutic choices. © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024.

Style	Citing Format
MLA	Nilforoushzadeh MA, et al.. "A Systematic Review of Interleukin-31 Inhibitors in the Treatment of Prurigo Nodularis." Inflammopharmacology, vol. 32, no. 2, 2024, pp. 991-1003.
APA	Nilforoushzadeh MA, Heidari N, Ghane Y, Heidari A, Hajikarimhamedani A, Hosseini S, Jaffary F, Najar Nobari M, Tavakolzadeh P, Najar Nobari N (2024). A Systematic Review of Interleukin-31 Inhibitors in the Treatment of Prurigo Nodularis. Inflammopharmacology, 32(2), 991-1003.
Chicago	Nilforoushzadeh MA, Heidari N, Ghane Y, Heidari A, Hajikarimhamedani A, Hosseini S, Jaffary F, Najar Nobari M, Tavakolzadeh P, Najar Nobari N. "A Systematic Review of Interleukin-31 Inhibitors in the Treatment of Prurigo Nodularis." Inflammopharmacology 32, no. 2 (2024): 991-1003.
Harvard	Nilforoushzadeh MA et al. (2024) 'A Systematic Review of Interleukin-31 Inhibitors in the Treatment of Prurigo Nodularis', Inflammopharmacology, 32(2), pp. 991-1003.
Vancouver	Nilforoushzadeh MA, Heidari N, Ghane Y, Heidari A, Hajikarimhamedani A, Hosseini S, et al.. A Systematic Review of Interleukin-31 Inhibitors in the Treatment of Prurigo Nodularis. Inflammopharmacology. 2024;32(2):991-1003.
BibTex	@article{ author = {Nilforoushzadeh MA and Heidari N and Ghane Y and Heidari A and Hajikarimhamedani A and Hosseini S and Jaffary F and Najar Nobari M and Tavakolzadeh P and Najar Nobari N}, title = {A Systematic Review of Interleukin-31 Inhibitors in the Treatment of Prurigo Nodularis}, journal = {Inflammopharmacology}, volume = {32}, number = {2}, pages = {991-1003}, year = {2024} }
RIS	TY - JOUR AU - Nilforoushzadeh MA AU - Heidari N AU - Ghane Y AU - Heidari A AU - Hajikarimhamedani A AU - Hosseini S AU - Jaffary F AU - Najar Nobari M AU - Tavakolzadeh P AU - Najar Nobari N TI - A Systematic Review of Interleukin-31 Inhibitors in the Treatment of Prurigo Nodularis JO - Inflammopharmacology VL - 32 IS - 2 SP - 991 EP - 1003 PY - 2024 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract